Airsupra (Albuterol Sulfate/Budesonide) Patent Expiration, LOE Window & CMS Spending
Airsupra (Albuterol Sulfate/Budesonide) by AstraZeneca: FDA Orange Book LOE 2030-05-28, 0 AB generics, $40.6M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | AstraZeneca |
| FDA Application & Pathway | N214070 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2030-05-28 |
| Orange Book Patents (*PED Extensions) | 1 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $40.6M |
| 2024 Medicare Part D Spend | $24.8M |
| 2024 Medicaid Spend | $15.8M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for AstraZeneca across sibling Meru public-data platforms.